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Abstract
Background: Many countries have reported an increase in the incidence of pertussis, which has become a global
public health concern.
Methods: In this study, the epidemiology of pertussis in Brazil was assessed retrospectively using surveillance data
gathered from case notification forms from 2007 to 2014.
Results: From 2007 to 2014, 80,068 suspected cases of pertussis were reported in Brazil. Of these, 24,612 (32 %)
were confirmed by various criteria. The annual distribution of confirmed cases demonstrated a significant increase
in incidence rate since 2012. A seasonal pattern in which cases occur most frequently between the end of spring
and midsummer has been identified. Among the confirmed cases, 34.5 % occurred in infants aged 0–2 months,
22.4 % occurred in infants aged 3–6 months, 21 % occurred in children aged 7 months to 4 years, and 8 % were
reported in adults >21 years. Of the confirmed cases, 47.2 % met only clinical criteria, 15.5 % met clinical and
epidemiological criteria, and 36.6 % were confirmed in a laboratory. The overall case fatality rate was 2.1 %,
reaching 4.7 % among infants aged 0–2 months. The complications most commonly reported in the notification
forms were pneumonia, encephalitis, dehydration, otitis, and malnutrition. Of the confirmed cases, 23.1 % occurred
in subjects who received at least 3 doses of the pertussis vaccine. Within this group, there were 1098 infants aged 7
to 15 months and 2079 children aged 16 months to 4 years. In 2012, 18 states did not achieve 95 % immunization
coverage, a number that dropped to 10 and 6 in 2013 and 2014, respectively.
Conclusions: Brazil’s main challenges in facing pertussis resurgence will be to offer the best quality medical
attention to reduce mortality, to improve the infrastructure for laboratory diagnosis and to increase vaccination
coverage. Additional studies to assess the effectiveness of the current vaccination schedule and basic research on
the genetics and evolution of circulating B. pertussis strains are also needed.
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Background
An increasing incidence of pertussis (whooping cough) has
been reported in many countries and currently represents a
global public health concern [1, 2]. The disease is a poten-
tially lethal, highly contagious respiratory tract infection
caused by the gram-negative bacteria Bordetella pertussis.
B. bronchiseptica, B. parapertussis, and B. holmesii can also
cause the disease in humans [3, 4]. A pertussis-like syn-
drome can be caused by respiratory viruses, mycoplasmas,
and other bacteria, such as Haemophilus influenzae and
Streptococcus pneumoniae [5].
Pertussis has an incubation period ranging from 5 to
21 days. B. pertussis infects the respiratory epithelium of
trachea, bronchi and bronchioles, causing an accumula-
tion of mucus and debris in the airways [6]. Clinically,
the disease is characterized by a paroxysmal cough and
fever and is frequently complicated by episodes of ap-
noea and cyanosis [7]. The majority of fatal cases have are
among patients who develop bronchopneumonia caused by
B. pertussis or a co-infection with other bacteria [6].
Pertussis is a vaccine-preventable disease. The incidence
has been reduced drastically in all countries that have
achieved satisfactory levels of vaccine coverage. Pertussis
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vaccines are combined with diphtheria and tetanus tox-
oids to produce the diphtheria-tetanus-pertussis (DTP)
trivalent vaccine. More recently, adding the hepatitis B
virus, H. influenzae type B antigens, and/or inactivated
poliovirus has led to the development of tetravalent and
pentavalent vaccines [8].
The first generation of vaccines, still widely used in de-
veloping countries, contains heat-killed whole B. pertussis
cells (wP) obtained from cultures. These vaccines are
highly immunogenic and effective, although they are asso-
ciated with potentially severe side effects such as febrile
seizures [9]. Acellular (aP) vaccines are used in developed
countries and are significantly less reactogenic, containing
distinct combinations of three to five of the following anti-
gens: pertussis toxin, filamentous hemagglutinin, pertactin,
fimbrial antigen 2, and fimbrial antigen 3 [10–12].
In 2002, the Brazilian National Immunization Pro-
gram (NIP) replaced the first three doses of the
diphtheria-tetanus-whole pertussis (DTwP) vaccine with
the tetravalent vaccine DTwP +H. influenzae type B
(DTwP-Hib). In 2012, this vaccine was replaced by the
pentavalent vaccine DTwP +H. influenzae type B +
hepatitis B (DTwP-Hib-HBV). Currently in Brazil, per-
tussis immunization is with 3 doses of the DTwP-Hib-
HBV vaccine given at 2, 4 and 6 months of age, followed
by two boosters with DTwP at 15 and 48 months of age.
The diphtheria-tetanus-acellular pertussis (DTaP) is
given only to infants who have had severe reactions to
the DTwP or in private vaccine clinics, and 2014, the
NIP began providing it to pregnant women.
Several hypotheses have been proposed to explain the
resurgence of the disease, including a decrease in the
immunogenicity of aP vaccines, which would lead to
early weaning of immunity and result in B. pertussis cir-
culating among adolescents and adults and spreading
from them to young infants who are not fully immu-
nized. It has also been proposed that B. pertussis may
have undergone a genetic evolution associated with the
selective pressure of vaccines. A significant increase in
the pertussis incidence rate has been observed in Brazil
in recent years [13]. This study aims to describe aspects
of the pertussis resurgence in Brazil, including the spa-
tiotemporal distribution, case fatality rates, confirmation
criteria and patient vaccination status.
Methods
The epidemiology of pertussis in Brazil was studied using
surveillance data that were retrospectively gathered from
case notification forms from 2007 to 2014. Data that are
generally not freely accessible were made available for this
study by the Brazilian Ministry of Health. Brazil has a popu-
lation of 202,768,562 inhabitants spread over 8,515,767 km2
and is divided into five geographical regions: the North
(which corresponds to the Amazon region with 16,983,485
inhabitants), the Northeast (53,081,510 inhabitants), the
Midwest (14,993,194 inhabitants), the Southeast (84,465,579
inhabitants) and the South (27,465,289 inhabitants). Brazil
has 26 federative units (states) and one Federal District.
Information concerning the vaccination coverage rates
were collected from the website of the Department of
Informatics of the Unified Health System (Datasus) [14].
Datasus calculates the immunization coverage rates as
the number of children with complete basic scheme in
the target age for a particular type of vaccine/number of
children in the target age X 100.
Pertussis is a reportable disease in Brazil. All suspected
cases treated at the Unified Health System are reported
using standardized forms sent to the Information System
for Notifiable Diseases (SINAN) of the Ministry of Health.
Pertussis notification forms have many variables, including
demographic and clinical data, treatment, confirmation
criteria, control measures adopted, pertussis vaccination
status, hospital discharge and death. This study was con-
ducted with the data available in pertussis reporting forms
sent to the Ministry of Health of Brazil from 2007 to 2014.
In Brazil, suspected pertussis cases are confirmed or dis-
carded at the health unit on the basis of clinical, epidemio-
logical or laboratory criteria. A case is confirmed with
clinical criteria if the blood count presents 20,000 or more
leukocytes/μL and 10,000 or more lymphocytes/μL, with a
negative or absent culture, lack of epidemiological link, or
without confirmation of aetiology. Epidemiological criteria
are met with a confirmed case of pertussis via laboratory
testing, which is performed between the beginnings of the
catarrhal period until three weeks after the beginning of the
disease paroxysmal period. Laboratory criteria are based on
the isolation of B. pertussis using a culture of nasopharyn-
geal secretion or positive polymerase chain reaction (PCR).
In a variable proportion of patients, a sample of nasopharyn-
geal secretion is collected and then forwarded to the Central
Laboratories of Public Health (LACENs). Confirmation rates
were calculated as the number of confirmed cases (by any
criteria)/number of notified (suspected) cases.
Population data from the Brazilian Institute of Geography
and Statistics, available at www.ibge.gov.br, were used for
calculation of incidence rates as the number of pertussis
confirmed (by any criteria) cases/population in a defined
municipality-state-whole country in a specific year X
100,000 inhabitants. The spatio-temporal and age distribu-
tion of cases was plotted and maps were produced with
Quantum Geographic Information System (QGIS) software
(QGIS Development Team, available at http://www.qgi-
s.org/en/site/). Case fatality rates in different regions, years,
and age groups were calculated as the number of deaths/
number of confirmed cases X 100. Complications that led
to fatalities were assessed. We also examined the vaccin-
ation status of notified cases, observing the utilization of
DTwP-Hib (tetravalent) vaccine until May 2012, followed
Guimarães et al. BMC Infectious Diseases  (2015) 15:442 Page 2 of 12
by the implementation of DTwP-Hib-HBV (pentavalent)
vaccine in June 2012. Children were considered vaccinated
if they had received three or more doses of DTwP-Hib or
DTwP-Hib-HBV. The proportion of vaccinated subjects
among confirmed and discarded cases was compared
through the chi-square test with a statistical significance of
5 %. Analyses were performed with EpiInfo 7.1.2.0 (Centers
for Disease Control and Prevention, Atlanta, Georgia,
USA).
Descriptive statistics are presented, with the distribu-
tion of cases by month, year and state, as well as the fre-
quencies of distinct diagnostic criteria used to confirm
the cases. The mean incidence rates of pertussis were
calculated and presented. The frequencies of clinical
complications in the cured group and in the group that
evolved to death were compared with chi-square test.
The confirmation rates in vaccinated and unvaccinated
groups in distinct age strata were also compared using
the chi-square test. Statistical significance was estab-
lished at p < 0.05.
The study was approved by the Research Ethics
Committee of the Oswaldo Cruz Institute/Fiocruz,
license number 39406914.0.0000.5248.
Results
Confirmed cases, incidence rates, spatio-temporal
and age distribution of pertussis in Brazil
Between January 2007 and December 2014, 80,068 sus-
pected cases of pertussis were reported in Brazil. Of
these, 24,612 (32 %) were confirmed using clinical, epi-
demiological or laboratory criteria. The annual distribu-
tion of confirmed cases demonstrated a significant
increase in the number of cases from 2012. The yearly
average of confirmed cases was 1226 per year between
2007 and 2011, reaching 6161 per year between 2012
and 2014. The confirmation rate was not related to the
increase in the number of cases being registered; the
highest rate of confirmation was in 2009 (34.7 %), and
the lowest was in 2010 (29.6 %). The annual distribution
of reported, and the confirmed cases and confirmation
rates are depicted in Fig. 1. The distribution of cases by
month showed an increase in the period from November
to February, as shown in Fig. 2. Therefore, a seasonal pat-
tern, in which cases occur most frequently between the
end of spring and midsummer in Southern Hemisphere,
has been identified. This seasonality was observed in all
five Brazilian regions, but seems to be more marked in the
South and Southeast. The annual incidence rates between
2007 and 2010 ranged from 0.32 cases per 100,000 to 0.75
per 100,000, showing an increase in 2011 and reaching
1.17 per 100,000, and then rising to 2.81 per 100,000 in
2012, 3.2 per 100,000 in 2013, and 3.25 per 100,000 in
2014 (not shown). During the epidemic period, the
mean annual incidence rate was 2.6 cases per
100,000, compared with 0.51 per 100,000 in the
period from 2007 through 2010.
With respect to the distribution of cases by state, the
states of São Paulo, Espírito Santo, Rio Grande do Sul
and Paraná accounted for 53.7 % (n = 13,216) of the con-
firmed cases of pertussis. During the epidemic period,
when there were 19,522 confirmed cases, the Southeast
region recorded 47.7 % (n = 9311), followed by the
South with 20.5 % (n = 4000) and the Northeast with
20.4 % (n = 3988) (data not shown). The annual evolu-
tion of pertussis incidence rates from 2007 to 2014 in
the different Brazilian municipalities is shown in the
maps in Fig. 3. An increased incidence in many munici-
palities can be observed in 2012.
By studying the distribution of cases by age, we aimed
to identify the proportion of cases in age groups in
which immunization from vaccines is not expected.
These groups included infants aged 0 to 2 months and
Fig. 1 Absolute numbers of reported and confirmed cases of pertussis and confirmation rates (confirmed cases/reported cases X 100) in Brazil,
from 2007 to 2014 per year
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adults over the age of 21 years. The distribution is
shown in distinct years in Fig. 4. Among the confirmed
cases, 34.5 % (n = 8491) occurred in infants aged 0 to
2 months, and approximately 8 % (n = 1969) were re-
ported in adults older than 21 years of age. In observing
other age groups, it was noted that 22.4 % (n = 5513)
were children aged 3 to 6 months, i.e., in the process of
immunization, while 21 % (n = 5168) occurred in children
aged 7 months to 4 years old, who are expected to be im-
munized. It is observed that in the period 2012–2014, the
proportion of cases in children aged 0 to 6 months de-
creased, while the proportion of the reported pertussis
cases among children aged 16 months to 4 years and 5 to
14 years increased. Among the confirmed cases, 55.4 %
Fig. 2 Seasonality of pertussis in Brazil: Number of reported and confirmed cases in different regions of Brazil, by month, 2007–2014. The monthly
values represent the sum of confirmed cases between 2007 and 2014 in that particular month
Fig. 3 Maps showing distinct strata of pertussis incidence rates in the different Brazilian municipalities, from 2007 to 2014. The maps were made
with the QGIS program using study data
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(n = 13,626) occurred in females, 0.5 % (n = 73) of whom
were pregnant.
Confirmation criteria for pertussis cases in Brazil
It was observed that 47.2 % (n = 11,606) of the confirmed
cases met only the clinical criteria, 15.5 % (n = 3821) met
clinical and epidemiological criteria, and 36.6 % (n = 9017)
were laboratory confirmed by various methodologies, most
frequently the culture for B. pertussis of nasopharyngeal
secretions. Among the confirmed cases, the laboratory con-
firmation rate ranged from 24.9 % (2009) to 49.5 % (2011).
Important regional differences were also observed; São
Paulo showed the highest rates, reaching 80.2 % of labora-
tory confirmations over the period (Fig. 5).
Complications and case fatality rates
The overall case fatality rate among confirmed cases
was 2.1 % (528 per 24,612). However, it was observed
Fig. 4 Distribution of confirmed cases of pertussis by age group from 2007 to 2014. The values represent the proportion of cases registered in
each age group per year
Fig. 5 Distribution of the criteria used to confirm the diagnosis of pertussis in Brazil, 2007–2014. The values represent the proportion of cases that were
confirmed by each criteria, by state. RO = Roraima, AC = Acre, AM=Amazonas, RR = Roraima, PA = Pará, AP = Amapá, TO = Tocantins, MA=Maranhão,
PI = Piauí, CE = Ceará, RN = Rio Grande do Norte, PB = Paraíba, PE = Pernambuco, AL = Alagoas, SE = Sergipe, BA = Bahia, MG=Minas Gerais, ES = Espírito
Santo, RJ = Rio de Janeiro, SP = São Paulo, PR = Paraná, SC = Santa Catarina, RS = Rio Grande do Sul, MS =Mato Grosso do Sul, MT =Mato Grosso,
GO=Goiás, DF =Distrito Federal (Federal District)
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that among children under 3 months of age, mortality
was substantially higher, reaching 4.7 % (401/8494).
Figure 6 shows the annual distribution of pertussis-
associated deaths, the evolution of case fatality rates
from 2007 to 2014, and the mortality in specific age
groups. A comparison of the case fatality rates in dif-
ferent regions of Brazil demonstrates the lowest rates
in the South (1.3 %); Rio Grande do Sul state registered
the lowest fatality rate (0.8 %). The Midwest region
registered the highest case fatality rate among the
macro-regions (2.5 %); however the state with the high-
est proportion of deaths was Roraima (North Region),
which had a fatality rate of 11.4 % (Fig. 7). The compli-
cations most commonly reported in the notification
forms included pneumonia, encephalitis, dehydration,
otitis, and malnutrition. In Table 1, we compare the fre-
quency of these complications reported among the pa-
tients who progressed to hospital discharge or death in
different age groups. Significantly higher frequencies of
pneumonia, encephalitis, dehydration and malnutrition
were observed in the group of children who progressed
to death.
Vaccination status of notified and confirmed pertussis
cases and pertussis vaccine coverage
It was noted that 10,600 confirmed cases of pertussis
(43 % of the total) occurred in people over the age of
7 months (the age group that should have received a
minimum of 3 doses of vaccine against pertussis). Of
this group, there was information about the vaccination
status of 6948 subjects. These cases were divided into
two groups: fully vaccinated (3 doses), with 5687 sub-
jects, and incompletely vaccinated (less than 3 doses),
with 1261 individuals. Thus, at least 23.1 % of the con-
firmed pertussis cases occurred in subjects who had re-
ceived at least 3 doses of the pertussis vaccine. Within
this group, there were 2079 children aged 16 months to
4 years and 1098 infants aged 7–15 months. Thus, it can
be considered that 12.9 %, i.e., (2079 + 1098)/24.612
cases of pertussis confirmed in Brazil between 2007 and
2014, occurred in fully immunized infants and children
aged 7 months to 4 years. Among these 3177 cases, 911
were confirmed using laboratory criteria; this value cor-
responds to 3.7 % of confirmed pertussis cases in Brazil
between 2007 and 2014. Among the 1261 cases reported
Fig. 6 Number of deaths and pertussis case fatality rates in Brazil, from 2007 to 2014 in different age groups. Case fatality rates were calculated as
the number of deaths/number of confirmed cases X 100
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in incompletely vaccinated subjects older than 7 months
of age, the predominant age group was between 7 and
15 months (n = 515).
Table 2 shows that the confirmation rates were signifi-
cantly lower in children with a complete vaccination
schedule (3 or more doses) compared with those with in-
complete immunization (2 doses or less), both in the
group aged 7 to 15 months and in the group aged
16 months to 4 years. However, beginning in June 2012,
which coincided with the replacement of DTwP-Hib by
the DTwP-Hib-HBV vaccine, the difference between the
confirmation rates among completely and incompletely
vaccinated children decreased, primarily in the group aged
16 months to 4 years.
In 2007, two states did not reach 95 % vaccination
coverage, and this number increased to six states in
2008. In 2012, 18 states did not achieve 95 %
immunization coverage, a number that dropped to ten
and six in 2013 and 2014, respectively (Fig. 8). As pre-
sented in Fig. 9, during the pre-epidemic period
(2007–2011), there was a trend of correlation between
pertussis incidence and vaccine coverage (R = 0.358;
p = 0.067). Nevertheless, from 2012 to 2014, when
incidence rates reached epidemic levels, such correl-
ation was not observed (R = 0.059; p = 0.769).
Discussion
A global resurgence of pertussis has been observed be-
ginning in the 1990s and the early 21st century. This
study demonstrates a re-emergence of pertussis in Brazil,
especially since 2012. In the US, since 1993, the inci-
dence of pertussis has increased, reaching over 25,000
cases per year in 2004 and 2005, 48,277 cases in 2012,
and approximately 28,000 cases per year in 2013 and
2014 [15], with some localized outbreaks [2, 16, 17]. In
Europe, most countries recorded an increase in the
number of cases, especially the Netherlands, UK,
Denmark and Norway. Between 2003 and 2007, the
overall average annual incidence was 4.1/100,000, rising
to 4.9/100,000 in 2009 [18–20]. In some countries, such
as the Netherlands, abrupt increases occurred [21]. Data
from this study suggest that epidemic levels were
reached in Brazil in 2011, increased in 2012, and reached
another peak in 2014. However, these values are still
below those observed in other countries, such as in
Europe, possibly because of underreporting.
In any epidemiological surveillance system, there is
concern about underreporting. It has been demonstrated
through capture-recapture methods that pertussis is sig-
nificantly underreported; in the US, it is likely that the
actual number of cases is 5–6 times than the reported
Fig. 7 Case-fatality rates of pertussis in Brazil, from 2007 to 2014 in different states and regions. Case fatality rates were calculated as the number
of deaths/number of confirmed cases X 100
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number. This failure to report cases may be even greater
for teenagers and adults because the symptoms are usually
mild and may go unnoticed [22–24]. Thus, the actual state
of the disease in Brazil may be even more alarming.
Cyclic epidemic peaks of pertussis are observed in many
countries. The interval between these peaks varies from
one study to another, suggesting that they occur every 2–5
years [2, 6, 18, 25, 26]. Brazilian data show increases in the
years 1997, 1998, 2004 and 2005. This study shows in-
creasing incidence from 2011 to 2014; in 2014, it reached
the highest number of cases in 30 years [27].
This study shows that pertussis has a clear seasonal
pattern in Brazil, with an increase in the number of
cases between late spring and summer (in the Southern
Hemisphere), specifically in the months of November,
December, January and February and especially in South
and Southeast regions. Similarly, it has been reported
that in the Northern Hemisphere, pertussis occurs most
frequently in summer and autumn [18]. Interestingly, in
Brazil, other acute respiratory tract infections are more
common between the autumn and spring and peak in
the winter [28]. These differences in seasonal patterns
may be useful for identifying and diagnosing pertussis.
Table 2 Pertussis confirmation rates by vaccination status in different periods and age groups, Brazil, 2007–2014
Confirmation rates
Notified cases (N) Fully vaccinated Incompletely vaccinated or unvaccinated p-value
Period/Age group
Jan 2007 – May 2012
7–15 months 1797 379/1292 (29,3 %) 212/505 (42 %) <0.001
16–48 months 3319 809/2964 (27.3 %) 132/355 (37.2 %) <0.001
Period /Age group
Jun 2012–Dec 2014
7–15 months 3635 719/2722 (26.4 %) 303/913 (33.2 %) <0.001
16–48 months 9283 2659/8548 (31.1 %) 261/735 (35.5 %) 0.013
Table 1 Frequency of different complications in fatal and non-fatal pertussis cases in different age groups in Brazil, 2007–2014. The
rates displayed are the number of children with the specific complication/total number of children in each category (cured or fatal
cases). Comparison of proportions was performed with the chi-square test
Complications
Age group Pneumonia Encephalopathy Dehydration Otitis Malnutrition
0–2 months Cured cases 1237/6787 (18.2 %) 88/6763 (1.3 %) 159/6778 (2.3 %) 44/6748 (0.7 %) 71/6765 (1 %)
Fatal cases 233/370 (63 %) 24/346 (6.9 %) 34/351 (9.7 %) 2/341 (0.6 %) 16/349 (4.6 %)
p-Value <0.001 <0.001 <0.001 0.84 <0.001
3–6 months Cured cases 701/4550 (15.4 %) 49/4534 (1.1 %) 117/4533 (2.6 %) 64/4523 (1.4 %) 50/4526 (1.1 %)
Fatal cases 57/83 (68.7 %) 9/78 (11.5 %) 10/79 (12.6 %) 2/78 (2.6 %) 4/78 (5.1 %)
p-Value <0.001 <0.001 <0.001 0.39 0.006
7–15 months Cured cases 243/1764 (13.8 %) 14/1757 (0.8 %) 44/1758 (2.5 %) 46/1756 (2.6 %) 29/1758 (1.6 %)
Fatal cases 13/21 (61.9 %) 1/19 (5.2 %) 0 1/20 (5 %) 0
p-Value <0.001 0.39 - 0.96 -
16 months–4 years Cured cases 236/2612 (9 %) 15/2610 (0.6 %) 53/2615 (2 %) 51/2607 (2 %) 33/2609 (1.3 %)
Fatal cases 3/10 (30 %) 0 0 0 2/10 (20 %)
p-Value 0.08 - - - <0.001
5–14 years Cured cases 115/2557 (4.5 %) 9/2550 (0.3 %) 42/2558 (1.6 %) 64/2555 (2.5 %) 23/2551 (0.9 %)
Fatal cases 1/4 (25 %) 1/4 (25 %) 0 0 0
p-Value 0.44 <0.001 - - -
>15 years Cured cases 83/2152 (3.9 %) 5/2151 (0.2 %) 18/2154 (0.8 %) 38/2153 (1.8 %) 8/2152 (0.4 %)
Fatal cases 1/4 (25 %) 0 0 0 1/4 (25 %)
p-Value 0.37 - - - <0.001
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Fig. 8 Pertussis vaccine coverage in different Brazilian states by year, from 2007 to 2014. Immunization coverage rates are calculated as the number of
children with complete basic scheme in the target age for a particular type of vaccine/number of children in the target age X 100 in different Brazilian
states. The maps were made with the QGIS program using study data
Fig. 9 Scatter diagrams showing the correlation between average annual pertussis vaccination coverage (number of children with complete
basic scheme in the target age for a particular type of vaccine/number of children in the target age X 100) and average annual pertussis
incidence (number of pertussis confirmed [by any criteria] cases/population in each state in a specific year X 100,000 inhabitants) by state in two
different periods: 2007–2011 (diphtheria-tetanus- whole pertussis + H. influenzae type B vaccine) and 2012–2014 (diphtheria-tetanus- whole
pertussis + H. influenzae type B + hepatitis B vaccine). From 2007 to 2011, R = 0.358; p = 0.067. From 2012 to 2014, R = 0.059; p = 0.769
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The age distribution of pertussis cases vary between
the distinct regions of the world and from one period to
another. During an epidemic in the US, the incidence
was higher among children under 6 months of age; dur-
ing the second epidemic, the incidence increased consid-
erably for children aged 14–16 years [2, 17]. Similar
variations in age distribution have been reported in
Europe [20, 29].
In the present study, we found that 1/3 of the con-
firmed cases occurred in infants aged 0 to 2 months, an
age at which they have not received any dose of a per-
tussis vaccine. A little over half the cases occurred in
children under the age of seven months, i.e., while they
were in the process of immunization. During the period
of increased incidence (2012–2014), the proportion of
confirmed cases in not fully immunized subjects de-
creased, while an increase in the proportion of cases in
older children and adolescents was observed.
Regarding the diagnostic criteria used, most cases were
confirmed by clinical and epidemiological criteria, and
laboratory confirmation was obtained in a little more
than one-third of cases. This is a low proportion; how-
ever, it can be explained by the difficulties of obtaining a
nasopharyngeal swab in most hospitals and health centres.
Nevertheless, laboratory tests are important for confirm-
ing pertussis because clinical diagnosis can be difficult
[30–32]. In the US, the significant increase in the number
of cases may be associated with the introduction of more
accurate techniques, such as PCR [16, 33]. In Mexico,
there was a substantial increase in pertussis confirmations
when PCR testing was implemented [26]. Interestingly, in
Italy, the case definition is based on clinical criteria, and
laboratory confirmation is not routine [29]. In Spain, the
proportion of laboratory confirmation has gradually in-
creased, reaching 69 % [34]. In the US, each confirmed
case is linked to a positive laboratory test or is epidemio-
logically associated with a case confirmed by culture or
PCR [35]. Unfortunately, the culture of nasopharyngeal
secretions of B. pertussis, despite high specificity, presents
low sensitivity, and its applicability is subject to logistic
limitations. The state of São Paulo, which has used the
PCR technique since 2009, had the highest rate of labora-
tory confirmation of the country. In general, the Southern
and Southeastern regions had the highest laboratory con-
firmation rates in Brazil. Efforts to improve pertussis la-
boratory diagnosis capacity in Brazil should be undertaken,
health professionals involved in patient care in health ser-
vices should be engaged, and laboratory infrastructure
within the Unified Health System should be improved.
The pertussis complications are more prevalent in
children under one year of age. In this study, pneumonia
was the most commonly observed complication, espe-
cially in infants under 3 months of age. In California in
2010, 18.8 % of patients with pertussis had pneumonia.
In Russia, the most frequent complications were encephal-
opathy, followed by bronchitis and pneumonia [17, 36]. A
study in the state of Paraná in Brazil also showed that
pneumonia was the complication most often associated
with death [13]. The overall pertussis case fatality rate in
Brazil is higher than that of other countries. In Canada be-
tween 1991 and 1997, there was a fatality rate of 0.9 %,
less than half the rate observed in Brazil between 2007
and 2014 [37, 38]. Additionally, the absolute number of
deaths from pertussis in Brazil is higher than those ob-
served in other countries. In England between 2001 and
2011, there were 48 deaths, the same number of deaths re-
ported in a 6-month period during the epidemic years of
the disease in Brazil [39]. In the US in 2013, there were
only 13 deaths from pertussis, with a case fatality rate of
0.02 % [40].
A global resurgence of pertussis has been noticed, es-
pecially in developed countries. Major hypotheses to ex-
plain it include a lower immunogenicity of aP compared
with wP vaccines, which would lead to the early wean-
ing of vaccine-induced immunity, the circulation of B.
pertussis among adolescents and adults and, from these
groups, the infection of infants who are not fully immu-
nized. This phenomenon may also be associated with
vaccines’ selective pressure on circulating strains, which
could cause them to block the antibodies produced by
immunization [39].
However, in Brazil, aP vaccines have never been intro-
duced universally and are available only in private vac-
cination clinics. The proportion of Brazilian children
and adults who have been immunized with aP vaccines
is not known. Vaccines containing the aP component are
available in the NIP only to pregnant women and chil-
dren who have developed serious side effects after the
use of wP vaccines. Thus, the increase in the incidence
of pertussis observed in recent years in Brazil should
have other possible explanations.
This study reveals that most cases of pertussis re-
ported in Brazil from 2007 to 2014 occurred in subjects
older than 6 months of age, with almost 13 % of these
cases recorded in fully immunized infants and children
aged 7 months to 4 years. Almost 1/3 of these cases
were laboratory confirmed. These data point to the pos-
sibility of some degree of vaccine escape in the context
of the DTwP-Hib-HBV vaccine. We observed that
among the reported cases, the proportion of confirmed
cases was significantly lower among fully vaccinated
children, demonstrating the protective effect of the vac-
cines, although our study did not aim to evaluate the ef-
fectiveness of the vaccines currently being used in Brazil.
Nevertheless, the difference in vaccination rates among
the confirmed and unconfirmed cases was lower during
the period of June 2012 through December 2014 com-
pared with the period of January 2007 through May 2012.
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This may point to a lower performance of DTwP-Hib-
HBV compared with the DTwP-Hib.
Interestingly, the increase in the incidence of pertussis
in Brazil coincides with the introduction of the DTwP-
Hib-HBV to the NIP in 2012, although an initial increase
in the incidence was already evident in 2011, before the
DTwP-Hib was replaced. It is also worth noting that
during this period, there was a relative reduction in vac-
cine coverage, which increased the number of states that
did not reach 95 % coverage. In the present study, we
found that 2 % of the confirmed cases occurred in in-
completely vaccinated infants older than 6 months of
age. During the pre-epidemic period there was a trend
for states with lower vaccination coverage present the
highest rates of incidence of pertussis. This pattern was
not observed in the 2012–2014 period.
In 2013, Brazil introduced the DaPT for pregnant women
as a measure to contain the resurgence of pertussis. Brazil’s
main challenges in facing pertussis resurgence will be to
offer the highest quality medical attention to reduce mortal-
ity, to improve the infrastructure for laboratory diagnoses,
and to maintain high vaccination coverage. Additional stud-
ies to assess the effectiveness of the current vaccination
schedule, including basic research on the genetics and evo-
lution of circulating B. pertussis strains, are also needed.
Conclusions
There has been a significant increase in the incidence of
pertussis in Brazil, especially since 2012. A little over
half of the cases occurred in infants younger than
7 months of age. Some of the confirmed cases may be
associated with primary vaccine failure, as some have oc-
curred in vaccinated children aged 7 months to 4 years.
Laboratory confirmation rates are less than ideal and
have large regional differences. Fatality rates are high
compared with those described in the literature; they are
significantly higher in infants and are strongly associated
with such complications as pneumonia, malnutrition
and dehydration. The increase in incidence coincides
with the introduction of the pentavalent vaccine and
with a relative reduction in vaccination coverage in sev-
eral states. Brazil’s challenges in facing rising pertussis
rates will be to offer the highest quality medical care,
improve the infrastructure for laboratory diagnostics and
maintain high vaccination coverage.
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